The Effect of Inhalation Agent on the QTc Interval During Liver Transplantation: Sub Study (NCT01886664)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01899248

Enrollment

Registered

2013-07-15

Start date

2012-12-31

Completion date

2013-11-30

Last updated

2014-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anesthesia, General

Brief summary

The purpose of this study is to assess the effects of inhalation agent on corrected QT interval duration during liver transplantation.

Interventions

DRUGSevoflurane

DRUGDesflurane

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* elective liver transplantation

Exclusion criteria

* age \< 18, age \> 65 * patient refusal * re-transplantation

Design outcomes

Primary

Measure	Time frame	Description
corrected QT interval (QTc interval)	up to postoperative day 1 after surgery	up to 10 minutes after tracheal intubation, up to 60 minutes after reperfusion, at 10 minutes after hepatectomy, at 10 minutes after biliary anastomosis, at skin closure, at the arrival on ICU, on postoperative day 1.

Secondary

Measure	Time frame	Description
proportion of patients whose QTc interval is more than 450 ms for men and 470 ms for women	up to postoperative day 1 after surgery	—
proportion of patients who have more than 500 ms of QTc interval	up to postoperative day 1 after surgery	—
Tp-e interval	up to postoperative day 1 after surgery	up to 10 minutes after tracheal intubation, up to 60 minutes after reperfusion, at 10 minutes after hepatectomy, at 10 minutes after biliary anastomosis, at skin closure, at the arrival on ICU, on postoperative day 1.

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026